Inactive Instrument

AEON Biopharma, Inc. Nasdaq

Equities

AEON

US00775E1029

Biotechnology & Medical Research

AEON Biopharma, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022

December 27, 2022 at 06:07 am EST

AEON Biopharma, Inc. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported net loss was USD 17.99 million compared to USD 49 million a year ago. Basic loss per share from continuing operations was USD 2.21 compared to USD 6.8 a year ago.

Latest news about AEON Biopharma, Inc.

AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Apr. 11	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
AEON Biopharma Shares Tumble on Wider Q4 Loss	Apr. 01	MT
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	Mar. 19	CI
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Mar. 18	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 19	MT
AEON Biopharma Says Cervical Dystonia Treatment Well-Tolerated in Phase 2 Study	Jan. 19	MT
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024	Jan. 18	CI
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	Dec. 12	CI
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
AEON Biopharma Reports Mid-Stage Migraine Trial Misses Statistical Significance	23-10-19	MT
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	23-10-19	CI
AEON Biopharma, Inc.(NYSEAM:AEON) added to S&P TMI Index	23-09-18	CI
Top Premarket Gainers	23-08-30	MT
AEON Biopharma, Inc. Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia At the International Parkinson and Movement Disorders Society Congress®	23-08-29	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	23-08-24	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-08-24	MT
Sector Update: Health Care	23-08-24	MT
AEON Biopharma Gets Notice of Allowance for Soon-to-Issue US Patent Covering Its Migraine Treatment Candidate	23-08-24	MT
HC Wainwright Starts AEON Biopharma at Buy With $18 Price Target	23-08-18	MT

Chart AEON Biopharma, Inc.

Duration

Period

More charts

Company Profile

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.30%	104B
REGENERON PHARMACEUTICALS, INC.	+3.54%	97.42B
ARGENX SE	-0.03%	22.2B
BIONTECH SE	-16.88%	21.23B
GENMAB A/S	-10.58%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-17.95%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.24%	13.98B
SAREPTA THERAPEUTICS, INC.	+27.50%	11.66B

Bio Therapeutic Drugs